AR017523A1 - Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones - Google Patents
Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composicionesInfo
- Publication number
- AR017523A1 AR017523A1 ARP980105363A ARP980105363A AR017523A1 AR 017523 A1 AR017523 A1 AR 017523A1 AR P980105363 A ARP980105363 A AR P980105363A AR P980105363 A ARP980105363 A AR P980105363A AR 017523 A1 AR017523 A1 AR 017523A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- procedure
- hydrogen
- single bond
- prepare
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010048768 Dermatosis Diseases 0.000 abstract 1
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000021328 arterial occlusion Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001123 epoprostenol Drugs 0.000 abstract 1
- 125000003700 epoxy group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se revelan compuestos de 4,5-diariloxazol caracterizados porque tienen la formula (I) donde R1 es hidrogeno o un grupo carboxiprotector, R2, R5, R6 y R7son hidrogeno o hidroxi, R3 y R4 cada uno son hidrogeno, o están combinados para formar un grupo epoxi o un enlace simple, R8 y R9 son grupos ariloopcionalmente sustituido, y X es un enlace simple o metileno, y además, R2 y R3 pueden estar combinados el uno con el otro para formar un enlace simple; ycuando R2, R5, R6 y R7 cada uno son hidrogeno,R3 y R4 forman un grupo expoxi; cuando R3 y R4 forman un enlace simple, al menos uno de R2, R5, R6 y R7 eshidroxi y el (los) otro(s) es (son) un hidrogeno y X es metileno, o sus sales, procedimiento para prepararlos, una composicion farmacéutica quelos incluye yel método para prepararla. Los compuestos (I) son agonistas de la prostaglandina I2 y por tanto son utiles para prevenir o tratar la obstruccion arterial,afecciones cerebrovasculares, cirrosis hepática, arterioesclerosis, isquemia cardíaca, isquemia cardíaca, hipertension dermatosis y enfermedades similares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP0032A AUPP003297A0 (en) | 1997-10-27 | 1997-10-27 | 4,5-diaryloxazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017523A1 true AR017523A1 (es) | 2001-09-12 |
Family
ID=3804308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105363A AR017523A1 (es) | 1997-10-27 | 1998-10-27 | Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6297267B1 (es) |
| EP (1) | EP1027340A1 (es) |
| JP (1) | JP2001521029A (es) |
| KR (1) | KR20010031204A (es) |
| CN (1) | CN1278252A (es) |
| AR (1) | AR017523A1 (es) |
| AU (1) | AUPP003297A0 (es) |
| BR (1) | BR9813281A (es) |
| CA (1) | CA2307952A1 (es) |
| HU (1) | HUP0004177A3 (es) |
| TW (1) | TW450966B (es) |
| WO (1) | WO1999021843A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP608898A0 (en) * | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| TWI316055B (es) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| KR101587071B1 (ko) * | 2008-07-23 | 2016-01-20 | 도레이 카부시키가이샤 | 만성 신부전 처치제 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344836A (en) * | 1991-11-11 | 1994-09-06 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
| US5362879A (en) * | 1993-04-15 | 1994-11-08 | Bristol-Myers Squibb Company | 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation |
| DK0736018T3 (da) * | 1993-12-20 | 2000-09-18 | Fujisawa Pharmaceutical Co | 4,5-Diaryloxazolderivater |
| ATE205479T1 (de) | 1994-03-10 | 2001-09-15 | Fujisawa Pharmaceutical Co | Naphtalen-derivate als prostaglandin i2 agonisten |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
-
1997
- 1997-10-27 AU AUPP0032A patent/AUPP003297A0/en not_active Abandoned
-
1998
- 1998-10-01 US US09/529,405 patent/US6297267B1/en not_active Expired - Fee Related
- 1998-10-01 CN CN98810632A patent/CN1278252A/zh active Pending
- 1998-10-01 HU HU0004177A patent/HUP0004177A3/hu unknown
- 1998-10-01 KR KR1020007004152A patent/KR20010031204A/ko not_active Withdrawn
- 1998-10-01 EP EP98945583A patent/EP1027340A1/en not_active Withdrawn
- 1998-10-01 JP JP2000517955A patent/JP2001521029A/ja active Pending
- 1998-10-01 WO PCT/JP1998/004455 patent/WO1999021843A1/en not_active Ceased
- 1998-10-01 BR BR9813281-4A patent/BR9813281A/pt not_active IP Right Cessation
- 1998-10-01 CA CA002307952A patent/CA2307952A1/en not_active Abandoned
- 1998-10-14 TW TW087117054A patent/TW450966B/zh not_active IP Right Cessation
- 1998-10-27 AR ARP980105363A patent/AR017523A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1278252A (zh) | 2000-12-27 |
| JP2001521029A (ja) | 2001-11-06 |
| TW450966B (en) | 2001-08-21 |
| CA2307952A1 (en) | 1999-05-06 |
| WO1999021843A1 (en) | 1999-05-06 |
| KR20010031204A (ko) | 2001-04-16 |
| US6297267B1 (en) | 2001-10-02 |
| HUP0004177A2 (hu) | 2001-05-28 |
| AUPP003297A0 (en) | 1997-11-20 |
| BR9813281A (pt) | 2000-08-22 |
| EP1027340A1 (en) | 2000-08-16 |
| HUP0004177A3 (en) | 2002-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041661A1 (es) | Compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos procesos para su preparacion y composiciones farmaceuticas que lo contienen | |
| AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
| BR9915895A (pt) | Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica | |
| ES2097859T3 (es) | Derivados de dihidropiridina, su preparacion y su utilizacion. | |
| ES2181443T3 (es) | Nuevos derivados de 3,3-difenilpropilaminas. | |
| ES2189330T3 (es) | Derivados heterociclicos n6 de la adenosina sustituidos. | |
| AR050181A1 (es) | Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
| AR004670A1 (es) | Compuestos derivados de acido amino sustituido arilo y heteroarilo carboxilico; composicion farmaceutica que los contiene; metodo para aliviar eldolor; procedimiento para preparar dichos compuestos y compuestos utiles como material de partida | |
| DK0521827T3 (da) | Farmakologisk virksomme hydrazinderivater og fremgangsmåde til deres fremstilling | |
| ES2195933T3 (es) | Nuevos derivados de flavonas, xantonas y cumarinas. | |
| FI871981A0 (fi) | Nya dopamin- -hydroxylas-inhibitorer. | |
| ES8401026A1 (es) | Procedimiento para la obtencion de acidos 1-carboxi-(azaalcanoil o azaaralcanoil)-indolin-2-carboxilicos. | |
| AR017127A1 (es) | Nuevos compuestos de piperazina y piperidina, un metodo para su preparacion, composiciones farmaceuticas que las contienen, metodos para prepararlas y nuevos compuestos intermedios para dicho metodo. | |
| ES8305687A1 (es) | Procedimiento para la obtencion de fenileteres sustituidos. | |
| PE20001083A1 (es) | Derivados de mononitrato de isosorbide | |
| AR246520A1 (es) | Procedimiento para producir 6,11-dihidro-11-(4-piperidilideno)-5h-benzo¡5.6¿ciclohepta¡1,2-b¿piridinas y metodo para preparar una composicion que utiliza el compuesto asi obtenido. | |
| AR043537A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
| AR017523A1 (es) | Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones | |
| AR012157A1 (es) | Derivados de piridina, composiciones farmaceuticas que los contienen y procedimiento para la preparacion de dichos derivados. | |
| AR024222A1 (es) | Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen | |
| AR018632A1 (es) | Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion. | |
| MX9603272A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| AR012990A1 (es) | Compuestos de benzo(5,6) cicloheptapiridina, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos como inhibidores de laproteina farnesil transferasa. | |
| ES2174582T3 (es) | Nuevos derivados de 1,2-ditiolano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ES2038654T3 (es) | Un procedimiento para preparar derivados de tianafteno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |